Genome-wide association studies (GWAS) have identified common variants of modest-effect size at hundreds of loci for common autoimmune diseases; however, a substantial fraction of heritability remains unexplained, to which rare variants may contribute 1,2 . To discover rare variants and test them for association with a phenotype, most studies re-sequence a small initial sample size and then genotype the discovered variants in a larger sample set 3-5 . This approach fails to analyse a large fraction of the rare variants present in the entire sample set. Here we perform simultaneous ampliconsequencing-based variant discovery and genotyping for coding exons of 25 GWAS risk genes in 41,911 UK residents of white European origin, comprising 24,892 subjects with six autoimmune disease phenotypes and 17,019 controls, and show that rare codingregion variants at known loci have a negligible role in common autoimmune disease susceptibility. These results do not support the rare-variant synthetic genome-wide-association hypothesis 6 (in which unobserved rare causal variants lead to association detected at common tag variants). Many known autoimmune disease risk loci contain multiple, independently associated, common and low-frequency variants, and so genes at these loci are a priori stronger candidates for harbouring rare coding-region variants than other genes. Our data indicate that the missing heritability for common autoimmune diseases may not be attributable to the rare coding-region variant portion of the allelic spectrum, but perhaps, as others have proposed, may be a result of many commonvariant loci of weak effect 7-10 .
There are only a handful of published examples of rare coding-region variants associated with common autoimmune diseases (although many examples in familial/Mendelian immune-mediated diseases). Coding-region variants in IFIH1 associated with type 1 diabetes (MAF in controls 5 0.67-2.2%) 3 , TYK2 with multiple autoimmune diseases 15 and IL23R with inflammatory bowel disease 5 , for example, are low frequency (which we define as MAF 5 0.5-5%) rather than particularly rare. In other examples, the existing evidence for association, and/or the effect sizes, are relatively weak (for example, CARD14 and psoriasis 16 , IL2RA and IL2RB and rheumatoid arthritis 17 ). The association of rare coding-region variants of NOD2 (also known as CARD15) in Crohn's disease probably provides the best example, albeit three low-frequency variants comprise over 80% of all the disease-causing mutations 18 . Most of the studies also lose power (especially for tests in which multiple rare variants are pooled into a single analysis, for example by gene) by initially sequencing only a small sample subset rather than testing the entire rare-variant content of a large case-control sample set. We sought to improve on these methods by performing highly multiplexed sequencing of sufficiently high quality to enable direct genotyping in the entirety of a large autoimmune disease casecontrol collection.
We selected subjects from a single population-individuals of white Northern-European ethnicity living in the UK (Methods)-to minimize any effects of population stratification. We selected to resequence all RefSeq exons for 25 genes from 20 GWAS-identified risk loci showing overlap between six common autoimmune disease phenotypes (autoimmune thyroid disease, coeliac disease, Crohn's disease, psoriasis, multiple sclerosis and type 1 diabetes). All genes studied were from risk loci for at least two phenotypes, all genes had known immune system function, 18 out of 20 loci had either a single candidate immune gene or all immune genes at a locus were selected (the remaining two loci had partial transcripts of another immune gene within the 0.1 centimorgan (cM) linkage disequilibrium block), and all genes and loci were densely genotyped on the Illumina ImmunoChip (Supplementary Table 1) 19 . We attempted high-throughput sequencing of 52,224 samples (including positive and negative controls, and repeats). We performed extensive quality control on both samples and variant calls (Methods). The final data set comprised 41,911 phenotyped individuals (autoimmune disease cases and controls), with ImmunoChip array genotypes available for 32,806 of these individuals (Supplementary Table 2 ). We discovered 4,377 variant sites across all amplicons, and the genotype call rate was 99.9989% (reference homozygote as well as non-reference genotypes) across 41,911 individuals. Of these, 2,990 variants were in protein-coding regions (including exon splice sites) of the 25 genes (Table 1 and Supplementary Table 3 ); 97.1% of which are rare (MAF in 17,019 controls, ,0.5%); 73.6% are novel when compared with current published data sets (dbSNP137, 1000 Genomes Project, National Heart, Lung, and Blood Institute (NHLBI)) containing .6,000 individuals and 67.3% are novel compared to an unpublished data set of 25,994 exome-sequenced individuals (D. G. MacArthur, personal communication); and 68.9% were only seen in one (singleton) or two (doubleton) individuals. These proportions of novel, and rare, variants are similar to recent data from other large re-sequencing studies 12 .
Our very high coverage data (99.8% of 183.4 million (site X sample) genotype calls had a read depth of $40 and 96.6% had a read depth of .100; Supplementary Fig. 1 ) enabled stringent data filtering on call rate per sample, per variant site, and other criteria (Methods). To confirm data quality, we performed further experiments and analyses as follows: (1) we genotyped one control sample 296 times (on different 48-sample microfluidic chips), and the genotype call error rate was two non-consensus genotype calls of 1,295,581 called genotypes (0.00015%); (2) 32,806 out of 41,911 subjects also had dense ImmunoChip genotyping data at the 25 genes, and genotype concordance at 91 variant sites genotyped on both platforms was 99.994%; (3) transition/transversion (Ti/Tv) rates, a quality-control measure based on expected human mutation types, were 2.434 at coding-region variants (2.427 at singletons), 2.44 at rare (MAF , 0.5%) variants (2.437 at singletons) and 2.275 at novel variants (2.273 at singletons) (definitions in Table 1 ); (4) we selected all (35) nonsense single nucleotide variants (SNVs) and all (39) frameshift insertions/deletions (indels) in the ImmunoChip-genotyped samples for Sanger sequencing: two variants failed assay/PCR (polymerase chain reaction) design and there was one false-positive SNV and one false-positive indel (overall false-positive rate 5 2.8%). All 70 validated SNVs and indels had the same alleles in high-throughput and Sanger-sequencing 
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assays; (5) proportions of rare, and of known, variants were similar to those found by other large sequencing studies, and we identified no common or low-frequency novel variant sites. We first attempted to identify any low-frequency or rare variants of larger effect. We performed for each coding-region variant and each of seven phenotypes (including all autoimmune disease cases combined) a single-variant association analysis. Only previously reported loci were observed with common variants (MAF . 5%), as expected. We identified three low-frequency (MAF 5 0.5-5%) and rare (MAF in 17,019 controls 5 ,0.5%) exonic variants with single SNP association P , 10 24 (chosen as a partial Bonferroni multiple testing correction for 25 genes and 7 phenotypes, but not correcting for all variants per gene) (Supplementary Table 4 and Supplementary Data). We next analysed low-frequency and rare exonic variants, conditioning on common-variant non-coding signals at each locus, and observed no additional association signals (Supplementary Data). An association between type 1 diabetes and the low-frequency UBASH3A SNP rs17114930 was observed, but conditional regression analysis showed this signal to be secondary to a stronger common-frequency variant/ haplotype previously identified by GWAS 20 . We identified novel lowfrequency (nearly 'common' as MAF in 17,019 controls 5 4.97%) NCF2 coding-region variant associations with coeliac disease at two SNPs (rs17849502, nonsynonymous; rs17849501, synonymous; in almost complete linkage disequilibrium r 2 5 0.992). Both variants were present on the Illumina ImmunoChip, but just failed qualitycontrol criteria in our previous coeliac disease study owing to missing data 19 . We replicated the UK findings in 4,313 coeliac cases and 3,954 controls (European samples, Methods; rs17849502 P 5 4.46 3 10 25 (Cochran-Mantel-Haenszel test), odds ratio 1.35 (95% CI 5 1.17-1.55)). Logistic regression analysis conditioning on rs17849502 in the UK re-sequencing data set revealed no further single-variant coeliac disease association signals below P , 10 24 . NCF2 is a component of the neutrophil NADPH oxidase respiratory burst complex. Different disease-causing mutations cause the recessive Mendelian phenotype chronic granulomatous disease. The rs17849502/H389Q variant is also associated with the autoimmune disease systemic lupus erythematosus 21 . Functional studies have shown that the minor allele of rs17849502/H389Q reduces the binding efficiency of NCF2 to the guanine nucleotide-exchange factor VAV1 (ref. 21) . These data now implicate a disease mechanism of impaired neutrophil function in coeliac disease, a condition previously thought to be of predominantly B-and T-cell-mediated immunopathogenesis, and where neutrophils may have a role in regulating adaptive immunity 22 .
We noted that even with ,7,000 cases and ,17,000 controls the power to detect association signals using single-variant tests for variants (MAF , 0.5%) of modest effect (for example, odds ratio , 3) is limited ( Supplementary Fig. 2 ) and therefore we performed gene-based pooledvariant association tests to better detect the combined effect of multiple variants. We defined coding-region variants as functional candidates if the variants were rare (MAF in 17,019 controls 5 ,0.5%) and predicted to be of potential functional impact (nonsynonymous, premature stop, splice-site altering; see Methods). We pooled variants (by gene) in analyses to detect different scenarios ( Fig. 1 and Supplementary Data) , including the C-alpha test, which can detect a combination of risk and protective variants; burden tests to detect either an excess of risk variants in cases or protective variants in controls; a modified version of the burden test using conditional regression and common-variant noncoding signals at a locus as covariates; a test to detect an excess of rare variants seen uniquely in cases (the case or control unique tests being particularly suitable for the study of the large numbers of singleton and doubleton variants we observe); and a test to detect an excess of rare variants seen uniquely in controls. The distribution of association statistics for all five pooled gene tests across each of the six or seven phenotypes tested was consistent with the global null of no association.
On the basis of these results, in the largest (to the best of our knowledge) human disease sample sequencing study to date, we find little support for a significant impact of rare coding-region variants in known risk genes for the autoimmune disease phenotypes tested. Our data provide little stimulus in support of large-scale whole-exome sequencing projects in common autoimmune diseases. Using average genetic-effect estimates from our data (Methods), over all loci and phenotypes we have tested, we estimate that rare variants contribute to less than 3% of the heritability explained by common variants at these known risk loci 23 .
METHODS SUMMARY
Sequencing. DNA (corresponding to exonic sequence of 25 autoimmune disease risk genes) was PCR-amplified in a multiplexed microfluidics assay (Fluidigm Access Array). PCR amplicons from a sample were pooled, and barcoded with one of 1,536 unique ten-base-pair sequences. Libraries of 1,536 samples were sequenced on Illumina HiSeq instruments. Reads were aligned to the GRCh37 human reference and SNVs and small indels called. Samples and called variants were extensively filtered on the basis of call rate and other criteria. Selected variants were validated by Sanger dideoxy sequencing. Genotype data from Illumina ImmunoChip array-based genotyping was merged with Fluidigm sequencingbased genotypes. Statistical analysis. Statistical analysis was performed in R, and using PLINK/SEQ software.
only call two alleles, therefore is not possible to determine whether these sequence genotype calls are real or errors. R code used for analysis is available from V.P. Estimation of average genetic effect contributed by rare variants. For each combination of locus by disease, we combined all rare functional variants (frequency , 0.5% in 1,000 Genomes/NHLBI data sets and nonsynonymous, LOF or splicing) in a burden statistic X and computed the combined frequency of X in the sample. Using a logistic regression model with the disease phenotype as outcome, we estimated the odds ratio associated with the burden variable X. This knowledge of frequency and odds ratio for the burden variable X enables the estimation of the average genetic effect (AGE, as defined in ref. 23 ) version of the variance explained. We then compared this variance at each combination of locus/gene with the variance explained by what we consider to be a typical common variant association (odds ratio 1.2, MAF 20%, assuming a single common variant per locus). To deal with the uncertainty in estimated odds ratio and obtain a confidence interval for this value, we randomly sampled the odds ratio from their estimated distribution for each pair of disease/locus. Averaging over the 150 combinations of 6 diseases by 25 loci, we estimate the ratio of heritability explained for all rare variants by all common variants to have a mean value of 1.6%, with a confidence interval of (1.2-2.3%). It is pointed out in ref. 23 that the AGE estimate can underestimate the true explained variance by rare variants. Nevertheless, assuming that rare variants are generally all risk or all protective at a given gene, their simulations also show that the underestimation is limited, in the range of a 25% decrease. Taking this conservative estimate of the under-estimation level, we find the upper bound of the 95% of the confidence interval to be 3.05%. Hence, our data indicate that the aggregate contribution of rare variants to the heritability (,0.5% MAF, and averaged over these loci/diseases) is unlikely to exceed approximately 3% of the heritability assigned to common variants. We acknowledge that a much larger underestimation (and therefore a much larger heritability explained for rare variants) is possible in the presence of a combination of high risk and highly protective rare variants at the same locus. Although we cannot exclude such scenario, it is unlikely to be widespread. We also assumed in our estimates that rare variants act additively at the log scale. Although this assumption is standard, we cannot exclude that a combination of rare variants results in a much stronger predictive outcome than rare variants individually, hence underestimating the heritability associated with rare variants.
